TrialJournal for immunotherapy of cancer2019

Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III-IV melanoma.

Robert H I Andtbacka et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.